
Although many patients will eventually relapse, the first remission is the deepest, according to one expert.

Although many patients will eventually relapse, the first remission is the deepest, according to one expert.

The FDA has issued a clinical hold on the phase 1 MELANI-01 trial evaluating the CAR T-cell product UCARTCS1A in the treatment of patient with relapsed/refractory multiple myeloma, according to Cellectis, the manufacturer of the product.

Caregivers of patients with multiple myeloma face similar challenges to those faced by the patients themselves.